Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines

Hashemzadeh, Nastaran; Dolatkhah, Mitra; Adibkia, Khosro; Aghanejad, Ayuob; Barzegar-Jalali, Mohammad; Omidi, Yadollah; Barar, Jaleh

doi:10.1016/j.lfs.2021.119110

Cited by 35 publications

(10 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the spherical shape of NPs could preferentially generate a Th1-type immune response and increase antibody and proinflammatory cytokine production [ 145 , 146 ]. Regarding cellular uptake, rod and filamentous shapes might have better biodistribution than other shapes [ 147 ], while elongated NPs normally avoid phagocytosis and exhibit longer circulation times. Another important parameter that can dramatically affect in vivo distribution, clearance, cellular uptake and the induction of immune response is the NPs’ size.…”

Section: Discussionmentioning

confidence: 99%

Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer is the most common type of malignancy and leading cause of cancer death among women worldwide. Despite the current revolutionary advances in the field of cancer immunotherapy, clinical response in breast cancer is frequently below expectations, in part due to various mechanisms of cancer immune escape that produce tumor variants that are resistant to treatment. Thus, a further understanding of the molecular events underlying immune evasion in breast cancer may guarantee a significant improvement in the clinical success of immunotherapy. Furthermore, nanomedicine provides a promising opportunity to enhance the efficacy of cancer immunotherapy by improving the delivery, retention and release of immunostimulatory agents in targeted cells and tumor tissues. Hence, it can be used to overcome tumor immune escape and increase tumor rejection in numerous malignancies, including breast cancer. In this review, we summarize the current status and emerging trends in nanomedicine-based strategies targeting cancer immune evasion and modulating the immunosuppressive tumor microenvironment, including the inhibition of immunosuppressive cells in the tumor area, the activation of dendritic cells and the stimulation of the specific antitumor T-cell response.

show abstract

Section: Discussionmentioning

confidence: 99%

Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[7][8][9][10] Nonetheless, there are limitations in efficient gene loading and expression due to their low serum stability, limited load capacity and uncontrollable release, [11] prompting the development of nanocomposite delivery platform like functionalized mesoporous silicon. [12,13] Mesoporous silica nanoparticles (MSNs) are extensively characterized and widely explored as potential vehicles for drug or gene due to low toxicity, large surface area, ordered pore structure, super high specific pore volume, tunable pore size, and easy surface modifiability. [14][15][16] In order to improve their loading capacity and controllable release ability, macro-porous silica nanoparticles have been developed for effective encapsulation.…”

Section: Introductionmentioning

confidence: 99%

“…Non‐viral gene vectors, including liposomes, polymeric nanoparticles and inorganic nanoparticle, have attracted significant attention for gene delivery due to their biocompatibility and ability to encapsulate a wide range of therapeutic molecules [7–10] . Nonetheless, there are limitations in efficient gene loading and expression due to their low serum stability, limited load capacity and uncontrollable release, [11] prompting the development of nanocomposite delivery platform like functionalized mesoporous silicon [12,13] …”

Section: Introductionmentioning

confidence: 99%

Temperature/GSH Dual Responsive Fluorinated Mesoporous Silica‐Coated Au NRs for Serum‐Resistant Gene Delivery**

Sun,

Fu,

Zhang

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

Mesoporous silica nanoparticles (MSN) are emerging as one of the most appealing candidates for gene carriers. Nevertheless, one major obstacle for their clinical application is the lack of efficient controlled release and gene delivery. In this study, a mesoporous silica‐modified gold nanorods (Au NRs) controlled release platform was synthesized. Then a thermosensitive copolymer was grafted to the surface of release platform, to impart the switching response of carrier under the photothermal of Au NRs. Fluorination were modified on the surface of MSN through a disulfide bond to achieve glutathione (GSH) response release and improve serum‐resistant ability. This gene carrier, with notable DNA condensation ability and negligible cytotoxicity, could be easily internalized into cells, enhanced green fluorescent protein expression in the presence of serum under laser irradiation. This work inspired us to solve the problem of traditional controllable sustained release and realize the performance of intracellular switch response to gene sustained release.

show abstract

“…Female breast cancer mortality rates in developing countries were much higher than in developed countries ( 1 ). Traditionally, BC has been classified based on the functional expression of steroid hormone receptors, including estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) ( 2 ). Triple-negative breast cancer (TNBC), the absence of expression of ER, PR, and HER2, is an extremely aggressive and heterogeneous tumor, accounting for 15%–20% of all breast cancer cases ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

In recent years, anti-PD-1/anti-PD-L1 has been considered to be a valuable therapeutic target and prognostic indicator for triple-negative breast cancer. We analyzed all publications published in the field from their inception until the present day in order to determine the current research status and hotspots. All related publications were searched on the Web of Science. Our research used R-studio (bibliometrix package), VOSviewer, and CiteSpace to analyze and obtain annual publications and citation information, articles, highest publication countries and affiliations, influential journals and authors, keyword analysis, and keyword bursts. In total, 851 documents were retrieved including 628 articles and 223 review articles. The output of publications increased year by year from 2013 to 2021. However, the average article citation times reached the top in 2014 but generally showed a downward trend from 2014 to 2021. It was an article written by Schmid et al. in 2018 that received the most citations. With regard to publications, citations, and link strength, among the top countries was the United States. Cancers was the most published journal. Schmid and Loi ranked top in total citations and h-index. Schmid has the largest M-index and Loi has the most publication. The keywords that received the most attention were “Immunotherapy”, “PD-L1”, “Triple-negative breast cancer”, “Tumor-infiltrating lymphocytes”, and “Expression”. According to the report, this current research focuses on immunotherapy for triple-negative breast cancer and the expression of PD-L1 and tumor-infiltrating lymphocytes (TILs). Pembrolizumab and Atezolizumab plus chemotherapy have completed the Phase 3 clinical trial. However, the biomarkers were limited in predicting the treatment prognosis. Through the scientometric analysis, we can understand the current research status and potential research points in this filed and provide research direction for researchers.

show abstract

Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines

Cited by 35 publications

References 167 publications

Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

Temperature/GSH Dual Responsive Fluorinated Mesoporous Silica‐Coated Au NRs for Serum‐Resistant Gene Delivery**

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis

Contact Info

Product

Resources

About